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Abstract: SARS-CoV-2 virus was first detected in late 2019 and circulated globally, causing COVID-19,
which is characterised by sub-clinical to severe disease in humans. Here, we investigate the serological
antibody responses to SARS-CoV-2 infection during acute and convalescent infection using a cohort
of (i) COVID-19 patients admitted to hospital, (ii) healthy individuals who had experienced ‘COVID-
19 like-illness’, and (iii) a cohort of healthy individuals prior to the emergence of SARS-CoV-2. We
compare SARS-CoV-2 specific antibody detection rates from four different serological methods,
virus neutralisation test (VNT), ID Screen® SARS-CoV-2-N IgG ELISA, Whole Antigen ELISA, and
lentivirus-based SARS-CoV-2 pseudotype virus neutralisation tests (pVNT). All methods were able to
detect prior infection with COVID-19, albeit with different relative sensitivities. The VNT and SARS-
CoV-2-N ELISA methods showed a strong correlation yet provided increased detection rates when
used in combination. A pVNT correlated strongly with SARS-CoV-2 VNT and was able to effectively
discriminate SARS-CoV-2 antibody positive and negative serum with the same efficiency as the VNT.
Moreover, the pVNT was performed with the same level of discrimination across multiple separate
institutions. Therefore, the pVNT is a sensitive, specific, and reproducible lower biosafety level
alternative to VNT for detecting SARS-CoV-2 antibodies for diagnostic and research applications.
Our data illustrate the potential utility of applying VNT or pVNT and ELISA antibody tests in parallel
to enhance the sensitivity of exposure to infection.
Keywords: coronavirus; COVID-19; SARS-CoV-2; spike glycoproteins; ELISA; IgG; neutralization;
cross-reactivity; convalescent plasma; pseudotype neutralisation
1. Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first linked to hu-
man disease following an outbreak characterised by respiratory distress in Wuhan, China
in late 2019. The causative agent was subsequently isolated and characterised from infected
humans [1] and was defined as a species of coronavirus; this virus was later classified as
a betacoronavirus and termed SARS-CoV-2 [2]. This novel coronavirus, SARS-CoV-2, is
Viruses 2021, 13, 713. https://doi.org/10.3390/v13040713 https://www.mdpi.com/journal/viruses
Viruses 2021, 13, 713 2 of 15
classified alongside six other coronaviruses known to infect humans. Of these, SARS-CoV,
MERS-CoV, and SARS-CoV-2 are associated with human disease, whilst HKU1, NL63,
OC43, and 229E are more often associated with asymptomatic or mild clinical progres-
sion [1]. From a clinical perspective, SARS-CoV-2 infection can lead to the development of
coronavirus disease 2019 (COVID-19), which was initially characterised, for example, by
fever, cough, and anosmia (loss of sense of smell) with resultant ageusia (a loss of sense
of taste) [3,4]. Clinical manifestations can vary significantly between affected individuals,
with no pathognomonic manifestations currently defined. COVID-19 manifests clinically
as asymptomatic (present in 30–40% of infected individuals), mild (present in ≈80% of
symptomatic cases), and severe disease (present in ≈20% of symptomatic cases), with case
fatality rates of between 0.4% and 11% [5]. In severe cases, mortality is generally attributed
to respiratory failure, pneumonia, systemic shock, or multi-organ dysfunction [4]. Since
its emergence, SARS-CoV-2 has demonstrated an ability to spread rapidly from human
to human, primarily through direct or indirect contact with respiratory secretions and
via inhalation of respiratory droplets and aerosols [6]. The World Health Organization
declared the outbreak a Public Health Emergency of International Concern on 12 January
2020 and a global pandemic on 11 March 2020 [7]. As of 27 February 2021, there have been
more than 113 million cases of COVID-19 globally with 2.5 million deaths attributed to
COVID-19 (https://coronavirus.jhu.edu/map.html (accessed on 20 March 2021)) [8].
SARS-CoV-2, is a positive-sense, single-stranded RNA (+ssRNA) virus, with a single
linear RNA segment as its genome [1]. SARS-CoV-2 virions are 50–200 nm in diameter
and consist of four main structural proteins, including the spike (S) glycoprotein (the
major immunogenic and antigenic virion component), the small envelope (E) glycoprotein,
the membrane (M) glycoprotein, and the nucleocapsid (N) protein [1] alongside several
accessory proteins. The S glycoprotein forms a homotrimer and protrudes from the surface
of the SARS-CoV-2 virion and infected cells, and it is thought to preferentially utilise the
angiotensin-converting enzyme 2 (ACE-2) receptor on host cells, facilitating internalisation
and infection. The S glycoprotein is also the major antigenic component of the SARS-CoV-2
virus [9].
Tracking infections and hospitalisations have demonstrated a cyclic pattern of in-
creasing and decreasing clinical prevalence, reflecting regional and national efforts to
reduce transmission [10]. Alongside efforts to diagnose and track infection, interest has
gathered in assessing immunological responses post infection [11]. The generation of
novel vaccines has further stimulated the evaluation of responses to both infection and
vaccination. As such, data regarding serological responses to infection, and any potentially
protective outcome of having been infected, either with or without the development of
clinical disease, have increased [11]. Indeed, serological tests have been widely heralded as
a potential key assays in any exit strategy from community lockdowns across the globe.
Several serological diagnostic technologies that assess specific immunity to pathogens
have been developed for SARS-CoV-2 including virus neutralisation tests (VNTs) [12],
viral pseudotype neutralisation tests (pVNTs) [13–15], and enzyme-linked immunosorbent
assays (ELISAs) [16–20].
VNTs are often considered as the ‘gold standard’ for serological detection, as the
results demonstrate inactivation of infectious virus, and as such, VNTs represent a strong
correlative indicator of protection from disease. Outputs are generated as a relative titre,
or dilution of serum, that inhibits virus-mediated cell death of a cultured mammalian
cell line [21] and often rely on the availability of virus isolate that cause cytopathic effect
(CPE) [22]. The level of neutralisation can be dependent on a variety of factors, including the
cell type used in the assay, the species from which the blood sample derives, and the isolate
of the virus being used in the test [21]. In the UK, the classical virus neutralisation test for
SARS-CoV-requires the use of containment level 3 (CL3) facilities [12]. However, there has
been interest in producing lower containment level alternatives to measure neutralising
antibodies to provide faster, more practical diagnostic assays. Recently, surrogate virus
neutralisation tests (sVNTs) have been described that use the principle of an ELISA to
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measure the neutralisation capacity of anti-SARS-CoV-2 antibodies directed against the
receptor binding domain [13,14]. In addition, lentiviral pseudotypes (PTs) containing SARS-
CoV-2 proteins have been used instead of SARS-CoV-2 virus to assess seroconversion [15].
While these PT assays provide a good correlation to ELISA, the diagnostic parameters and
correlations to classical virus neutralisation assay remain largely unexplored.
ELISA offers another platform for antibody testing of serum or plasma samples for the
presence of specific antibodies following infection with SARS-CoV-2 [16–20]. Existing SARS-
CoV-2 ELISA platforms generally utilise SARS-CoV-2 spike or nucleocapsid recombinant
antigens to identify the presence of binding antibodies. The sequential detection of IgM
followed by IgG antibody over time post-symptom-onset (PSO) in human patients has
been described, with early IgM (detected within the first week PSO) declining over time to
leave a longer lasting IgG response (detected within 1–3 weeks PSO) [16,20,23–25]. These
studies also suggest transient serological responses PSO, except perhaps for individuals
with higher titres [16,20,23–25]. Time PSO for antibody development and detection is
likewise acknowledged in the sensitivity estimates of antibody tests, suggesting higher
seropositivity levels from around 2 weeks PSO [26].
The development of serological tests to detect antibodies specific to SARS-CoV-2 was
originally limited by both the availability of sera with which to assess responses and, where
virus neutralisation is assessed, high biological containment facilities within which to
undertake live virus assays. The development of ELISA tests has likewise grown with the
increased availability of serum samples, virus, and viral proteins. Here, we compared the
neutralising and IgG antibody titres in COVID-19 patients at single and at multiple time
points PSO using a SARS-CoV-2 VNT and two separate ELISAs, comparing the sensitivity
and specificity of both methods. We also investigated the diagnostic application of these
tests used individually or in combination, and we propose and validate the diagnostic
application of a novel SARS-CoV-2 pVNT to provide an alternative COVID-19 functional
serological assay at a lower biological containment level. These data presented herein
provide information on the serological response in convalescent patients and provide a
series of tools for diagnostic and research application to control SARS-CoV-2.
2. Materials and Methods
2.1. Viruses
The SARS-CoV-2 virus strain 2019-nCoV/Italy-INMI1 (clade V) was acquired from
the European Virus Archive Global (EVAg) (008V-03893, www.european-virus-archive.com
and used for VNT and ELISA. The Wuhan-Hu-01 spike protein sequence was used for the
development of pseudotype assays. The complete sequence was submitted to GenBank
(SARS-CoV-2/INMI1-Isolate/2020/Italy: MT066156) and is available on GISAID website
(BetaCoV/Italy/INMI1-isl/2020: EPI_ISL_410545). For use outside of containment, the
virus was inactivated using beta-propiolactone (BPL) as described previously [27].
2.2. Sera
APHA Control sera—Archived human health surveillance samples (n = 138 total)
collected between January 2015 and February 2019 were used as a control cohort for
this study.
APHA COVID-19 positive sera—serum samples taken from APHA staff volunteers
who had experienced COVID-19-like symptoms, had isolated, and then returned to work.
Permission was obtained from all contributors prior to inclusion in the study.
University Hospital Southampton Foundation NHS Trust clinical panel—A total of
128 serum samples were collected from SARS-CoV-2 PCR-positive patients following ad-
mission to University Hospital Southampton Foundation NHS Trust between 20/03/2020
and 20/5/2020 as part of the CoV-19POC study [28]. All patients gave written informed
consent, or where unable to given consent, consultee assent was obtained. The trial was
approved by the South Central—Hampshire A Research Ethics Committee: REC reference
20/SC/0138, on the 16 March 2020. The protocol is available at: https://eprints.soton.ac.
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uk/439309/2/CoV_19POC_Protocol_v2_0_eprints.pdf (accessed on 30 August 2020). The
trial was prospectively registered; ISRCTN14966673, on the 18 March 2020.
2.3. Serum Processing
Human blood samples were centrifuged at 800× g for 5 min. The serum fraction was
transferred to a fresh screw cap tube within an MSC and heated at 56 ◦C for 30 min. Serum
samples were stored at 4 ◦C until required.
2.4. ELISAs
Whole Antigen ELISA—A BPL-inactivated SARS-CoV-2 antigen (iSARS-CoV-2) was
produced from Vero E6 cell cultures infected with the human strain 2019-nCoV/Italy-INMI1
(008V-03893) (courtesy National Institute for Infectious Diseases “Lazzaro Spallanzani”
IRCCS, Rome, Italy). BPL-treated uninfected Vero E6 cell culture extract was used as a
negative control. The dilution of supernatant used to coat ELISA plates was determined
in prior test runs using VNT-positive and control negative APHA serum samples. Each
serum sample was tested in a 2-well test, with the control antigen well subtracted from the
iSARS-CoV-2 antigen well. ELISA plates (Nunc Maxisorp) were coated with 5 µL/well of a
1/10 dilution of iSARS-CoV-2 or control antigen in carbonate coating buffer pH 9.6. Plates
were incubated overnight at 4 ◦C and then washed in PBS/0.1%Tween-20 before loading
test serum samples. Test sera were diluted 1/100 in a sample/conjugate buffer (PBS buffer
containing 1% Poly Vinyl Pyrrolidone (PVP-40, Sigma-Aldrich, Merck Life Sciences, UK),
0.001 M EDTA, and 0.005% Tween-20 and 50 µL/well was added to one iSARS-CoV-2
antigen well and one control antigen well per sample. Plates were incubated for 2 h at
room temperature, and after washing, 50 µL/well of Protein-A/G-HRP diluted 1:20,000 in
sample/conjugate buffer was added for one hour at room temperature. Plates were washed
and 100 µL/well of TMB was added for 8–10 min, the reaction was stopped by adding
100 µL/well 0.5 M H2SO4, and plates were read at 450 nm on an ELISA reader. ELISA
data were analysed using ∆OD450nm (iSARS-CoV-2 antigen minus the control antigen for
each sample).
The ID Screen® SARS-CoV-2-N IgG Indirect ELISA (SARS-COV-2-N) was used to
measure nucleocapsid protein-specific antibody. The test is validated for human samples
with a given diagnostic specificity of 99.9% (95%CI: 99.6–100%) and sensitivity of 93.3%
(95%CI: 78.8–98.2%) for those persons infected for more than 15 days. This test was carried
out following the manufacturer’s instructions. Raw ELISA data (OD450nm) was used for
data analysis.
2.5. SARS-CoV-2 Virus Neutralisation Test (VNT)
The VNT was adapted from Loeffen et al. [29], which was developed to detect
antibodies against Schmallenberg virus. In the 96-well plate format, in quadruplicate,
two-fold dilutions were made of the serum sample in virus growth media (Dulbecco’s
modified Eagle’s media (DMEM) (Gibco) supplemented with 2% foetal calf serum and
1% Penicillin/Streptomycin/Nystatin). Then, 100 TCID50 of SARS-CoV-2 virus (2019-
nCoV/Italy—INMI 1 (GISAID ID EPI_ISL_410545)) was added to each well. Plates were
sealed with a gas permeable plate sealer and incubated at 37 ◦C and 5% CO2 for 1 h. A
back titration of the input virus was performed for each aliquot used by two-fold serial
dilution in virus growth media. A negative, no virus control plate was also included. After
incubation, a suspension of 5 × 104 Vero E6 cells was added to each well. Plates were sealed
with a gas permeable plate sealer and incubated for 5 days at 37 ◦C and 5% CO2. Each well
was visualised daily for cytopathic effect (CPE) under a microscope. The titre of the virus
and the samples were calculated using the Spearman–Karber method and displayed as
inhibitory concentration 50% (IC50). The limit of detection was 2.82 IC50 i.e., one well out
of four at a specific dilution being positive for virus neutralisation. A valid test required (i)
the virus back titration to be 30 to 300 TCID50/well, (ii) absence of neutralisation in the
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negative control serum, (iii) absence of CPE in the “no virus control” plate, and (iv) the
positive control within 2 IC50.
2.6. Pseudotype Production
The generation and utilisation of SARS-CoV-2 pseudotypes has been described pre-
viously [30,31]. Briefly, HEK-293T cells were maintained in Dulbecco’s Modified Eagle’s
media (DMEM) plus 10% foetal calf serum and penicillin and streptomycin. After a 24 h
incubation, the cells were transfected with the HIV-1 gag-pol construct, pCMV-∆8.91 [32],
the firefly luciferase reporter construct pCSFLW [33], and pcDNA3-SARS2-S [34] at a ratio
of 1:1.5:1 respectively, again using Fugene 6 (Promega, Madison, WI, USA). Forty-eight h
later, supernatants were collected, filtered through a 0.45 µM filter, and titred on cells
transfected with pCAGGS-ACE2 and pCAGGS-TMPRSS2 at a ratio of 1:3 using Fugene 6.
Pseudotype particles were subsequently stored at −70 ◦C.
2.7. Pseudotype Virus Neutralisation Test (pVNT)
Twenty-four h prior to running the assay, HEK293T/17 cells were transfected with
pCAGGS-ACE2 and pCAGGS-TMPRSS2 at a ratio of 1:3 using Fugene6 (Promega, Madison,
WI, USA). In a 96-well plate, sera was initially diluted 1:40, and then, a 2-fold serial dilution
was undertaken across the plate. Then, 100 TCID50 of the SARS-CoV-2 pseudotype virus
that resulted in an output of 1 × 104 relative light units was added to the test sera and
incubated at 37 ◦C for 1 h before 2 × 104 transfected HEK293T/17 cells were added to the
sera/pseudotype virus mix. Following incubation for 48 h, the media was removed and
replaced with 50 µL serum free DMEM, 50 µL of Bright Glo (Promega, Madison, WI, USA)
reagent was also added at this stage. Luciferase activity was measured 2.5 min later using
an Infinite 200 PRO luminometer (TECAN, Männedorf, Switzerland) plate reader. IC50
values were determined as described by Ferrara and Temperton [30].
3. Results
3.1. Clinical Presentation across Sampled Cohorts
Serum samples were obtained from 103 adult patients admitted to University Hospital
Southampton Foundation NHS Trust displaying COVID-19 symptoms during the first
wave of the pandemic in the UK, between 20 March and 30 May 2020, as part of the
CoV19POC study [28]. All patients were PCR positive for SARS-CoV-2 RNA on upper
respiratory tract samples using the QiaStat-Dx Respiratory SARS-CoV-2 Panel (QIAGEN,
Hilden, Germany). All 103 patients had a serum sample taken on admission, 11 of these
had one further sample taken on average 13 days later, and 7 had two further samples
taken: one on average 11 days later and one on average 25 days later. The median (IQR)
age of patients was 61 (47 to 75) years, and 62 (61%) of 103 were male. The median (IQR)
duration of illness at presentation was 7 (4 to 10) days. The median (IQR) NEWS2 (National
early warning score 2) was 5 (3 to 7), and 89 (90%) of 99 had evidence of pneumonia on
their chest X-ray. Thirty (29%) of 103 were admitted to the intensive care unit, and 14 (14%)
of 101 died within 30 days of admission. The baseline characteristics and outcomes for
these patients are summarised in Table 1.
A further panel of samples were taken from individuals that had self-isolated follow-
ing a positive COVID-19 test result between 1/03/20 and 1/07/20 but who displayed only
mild clinical disease (cough, fever, or a loss in sense of taste or smell) and did not require
hospitalisation. From these (n = 3), serum samples were taken intermittently for a period
of 93 to 97 days post symptom onset, and antibody longevity was assessed. Furthermore,
negative control human serum were retrospectively assessed from 138 samples collected
prior to the emergence of SARS-CoV-2, through existing APHA staff health-surveillance
schemes (samples collected between January 2015 and February 2019). These three sample
sets were assessed in all three different serological assays to give a comparative readout of
the performance of each assay.
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Table 1. Baseline clinical characteristics and outcomes for patients admitted to University Hospital
NHS Foundation Trust.
Characteristic n = 102
Age, years 61 (47 to 75)
Male sex 62 (61)
Duration of illness, days * 7 (4 to 10)
Ct value of PCR 24 (15 to 32)
NEWS2 5 (3 to 7)
Pneumonia on CXR 89/99 (90)
Admission to ICU 30 (29)
30 day mortality 14/101 (14)
Data are presented as number (percentage) and median (interquartile range). Ct, cycle threshold; NEWS2, national
early warning score 2; ICU, intensive care unit; PCR, polymerase chain reaction; * Prior to admission.
3.2. Serological Screening in COVID-19 Positive Patients and Symptomatic Individuals Using
VNT and ELISA
Serum samples from the three cohorts were tested using a VNT and two ELISAs; an
in-house developed ‘Whole Antigen ELISA’ using BPL-inactivated cell culture SARS-CoV-2
virus, and a commercially available SARS-CoV-2-N ELISA (ID Screen® SARS-CoV-2-N IgG
Indirect ELISA), as a comparator (Figure 1A–C). The cohorts were tested using the three
methods in parallel, including (i) a group of PCR positive human patient sera from the
University Hospitals Southampton NHS Foundation Trust (n = 85—denoted “UHS+ve”);
(ii) a panel of sera taken at defined time points from individuals that had symptomatic
disease consistent with SARS-CoV-2 infection during the pandemic (n = 48; denoted “Sym”);
and (iii) a panel of human health surveillance sera taken pre-October 2019 as a negative
control group (n = 138; denoted “PreCOVID”).
Figure 1. Virus neutralisation test and ELISA results from a panel of COVID-19 PCR-positive cases (n = 85), symptomatic
individuals (n = 48), and healthy volunteers prior to the emergence of COVID-19 in humans (n = 138). (A) VNT; (B)
SARS-CoV-2-N ELISA; (C) Whole Antigen ELISA results from (i) a group of PCR positive human patient sera from
the University Hospitals Southampton NHS Foundation Trust (n = 85—denoted “UHS+ve”); (ii) a panel of sera from
individuals that had symptomatic disease consistent with SARS-CoV-2 infection during the pandemic (n = 48; denoted
“Sym”); and (iii) a panel of human health surveillance sera taken pre-October 2019 as a negative control group (n = 138;
denoted “PreCOVID”). Horizontal lines represent mean +/− SD. Dotted lines represents test cut-off values of 2.83 IC50,
0.215 OD450nm, and 0.49 ∆OD450nm for the VNT, SARS-CoV-2-N ELISA, and Whole Ag ELISA, respectively.
Six of the 48 serum samples from the Sym group were positive (above the limit of
detection of 2.83 IC50) for SARS-CoV-2 neutralising antibodies in the VNT (Figure 1A).
The SARS-CoV-2-N ELISA identified all six VNT-positive samples tested, while the whole
antigen ELISA identified 5/5 VNT-positive Sym samples tested (there was insufficient
volume to test for the 6th sample), plus two further Sym individuals that were VNT-
negative (Figure 1). Of the 85 UHS+ve individuals, 45 serum samples tested positive for
neutralising SARS-CoV-2 antibodies by VNT with the highest value of 109.2 and a mean
IC50 titre of 20.1 (Figure 1A). Using ELISA on the same samples, 47 were SARS-CoV-2-N
ELISA test-positive and 49 were whole antigen ELISA test-positive (Figure 1B,C). None of
Viruses 2021, 13, 713 7 of 15
the 138 Pre-COVID control serum samples collected between 2015 and 2019 demonstrated
any SARS-CoV-2 antibody neutralisation by VNT, but there was one positive result in each
of the ELISA tests (a different individual in for each test) (Figure 1).
The diagnostic cut-off for both ELISAs was determined using receiver operating
characteristic (ROC) analysis using the UHS+ve cohort (n = 85) as a positive control group
and the PreCOVID human sera as a negative control group (n = 138). The ROC analysis
demonstrated that the SARS-COV-2-N and whole antigen ELISAs had an equal specificity
of 97.8% for both tests (Figure S1A,B). In contrast, the Whole Antigen ELISA had a slightly
higher sensitivity than the SARS-CoV-2-N ELISA (57.7% compared to 55.3%, respectively)
as reflected by a higher Area Under the Curve measurement for the Whole Antigen ELISA
(Figure S1C). For the purpose of this analysis, test cut-offs providing a specificity of 97.8%
were used, producing cut-off values of 0.215 OD450nm and 0.49 ∆OD450nm for the SARS-
CoV-2-N ELISA and Whole Antigen ELISA respectively).
3.3. Longitudinal Assessment of COVID-19 Serological Responses over Time
Following this initial assessment on single time point samples, seropositivity over
a longitudinal time course was investigated. VNT and both ELISAs were performed on
serum samples obtained at multiple (maximum three) time points post admission from
the UHS+ve cohort. Of the 11 UHS+ve individuals, for which two sequential samples
were available, VNT and the Whole Antigen ELISA showed that six were positive at the
first time point, compared to seven positives using SARS-CoV-2-N ELISA (Figure 2A,C,E).
All UHS+ve samples were positive to all tests by the second time point. Of the seven
individuals for which three sequential samples were available (Figure 2B,D,F), four were
positive by VNT at the first time point, whilst five were positive by both ELISAs. All
UHS+ve samples were positive on all three tests at the second and third sampling time
points post admission.
Alongside the UHS+ve panel of hospital admission sera, three individuals in the Sym
group that had recovered from a short course of clinical disease consistent with COVID-
19 were sampled approximately every 14 days until 42 days and then monthly until 93
or 97 days. Serum samples were tested by both VNT and both ELISAs (Figure 2). The
neutralising antibody levels in these three individuals declined rapidly in the first 28 days
post symptom onset before plateauing or slowly declining until 93 or 97 days post infection
(Figure 3A). Similarly, the SARS-CoV-2-N ELISA showed a steady decline in antibody levels
for all individuals (although all remained sero-positive) from 28 days post symptom onset
until 93 or 97 days post symptom onset (Figure 3B). The Whole Antigen ELISA (Figure 3C)
demonstrated that for all individuals, a positive antibody response at the outset that was
sustained to similar levels throughout the testing period.
3.4. Comparative Performance of Serological Tests across Sample Cohorts
The VNT was compared to both ELISA tests using all 128 UHS+ve samples (Figure 4).
The VNT and SARS-CoV-2-N ELISA showed a strong correlation with an R2 of 0.7318,
suggesting comparability between these methods of detection (Figure 4A). In contrast, the
Whole Antigen ELISA had a poor correlation to VNT titres, producing an R2 of 0.2135
(Figure 4B). Overall, 80 (62.5%), 84 (65.6%), and 85 (66.4%) of the 128 UHS+ve serum
samples from 103 COVID-19 confirmed patients tested positive by the VNT, SARS-COV-
2-N ELISA, and Whole Antigen ELISA, respectively (Figure 4C), while 23 (18%) samples
tested negative by all assays. Test-positivity to the VNT and ELISA tests is illustrated by
Figure 4C.
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Figure 2. Sequential antibody testing of UHS PCR-positive individuals for which sequential samples were available.
Sequential samples from a group of PCR positive human patient sera from the University Hospitals Southampton NHS
Figure 2. N ELISA, and (E,F) Whole Antigen ELISA. (A,C,E) Eleven individuals had two sequential samples; (B,D,F) seven
individuals had three sequential samples. Dotted line represents test cut-off values of 2.83 IC50, 0.215 OD450nm, and 0.49
∆OD450nm for the VNT, SARS-CoV-2-N ELISA, and Whole Ag ELISA, respectively.
Figure 3. Sequential antibody testing of three VNT-positive COVID symptomatic individuals. Samples were taken for up to
93 or 97 days post symptom onset from three COVID-19 symptomatic individuals tested in Figure 1. Serum was tested
using (A) VNT, (B) IDVET ELISA, and (C) Whole Antigen ELISA. The dotted line represents test cut-off values of 2.83 IC50,
0.215 OD450nm, and 0.49 ∆OD450nm for the VNT, SARS-CoV-2-N ELISA, and Whole Ag ELISA, respectively.
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Figure 4. Comparison between SARS-CoV-2-N ELISA, Whole Antigen ELISA, and SARS-CoV-2 virus neutralisation test.
Comparison between VNT titres and (A) SARS-CoV-2-N ELISA and (B) Whole Antigen ELISA for all 128 serum samples
from 103 separate PCR positive human patients from the University Hospitals Southampton NHS Foundation Trust. (C)
Test-positives identified by the three tests are shown in the Venn diagram.
Then, ELISA test performance was compared on the initial entry sample for each of
the 103 UHS PCR-positive patients, and the ELISA results are shown in context with VNT
test-positivity (Table S1). These data indicated that using a combination of VNT plus an
ELISA test in parallel can increase the sensitivity of antibody detection and that the added
value of the antibody test may depend upon the test used. Our data showed that VNT
alone detected 53% (55 out of 103) of UHS+ve individuals, VNT plus SARS-CoV-2-N ELISA
detected 65% (55 + 12 out of 103) of UHS+ve individuals, and VNT plus Whole Antigen
ELISA detected 75% (55 plus 22 out of 103) of UHS+ve individuals.
3.5. Evaluation of a Lower Containment Level Pseudotype Assay and Comparison with VNT
Following the evaluation of sera in a VNT using live virus, panels of sera were assessed
using a lentiviral pseudotype virus expressing the SARS-CoV-2 surface glycoprotein in a
pseudotype virus neutralisation test (pVNT) [34]. To determine the ability of pseudotype
virus to be neutralised by SARS-CoV-2 antibody positive sera, a panel of serum from the
Sym individuals, previously analysed in Figure 1, were subsequently analysed by pVNT.
In the pVNT, five positive samples were identified that were also VNT positive (Figure 5A)
(the sixth sample identified as positive by VNA was not analysed by pseudotype virus).
To determine the robustness of the pVNT, the serum samples from the Sym group panel
were also tested using the pVNT method but with an independently produced lentivirus
pseudotype stock generated at the University of Kent (UoK).
Analysis of pVNT generated and performed at the UoK determined four positive
samples against SARS-CoV-2 (Figure 5A) (the fifth and sixth VNA positive sample was not
analysed as samples had been depleted), demonstrating 100% diagnostic reproducibility
at two independent institutions, with two independently produced batches of lentivirus
pseudotypes. To determine the specificity and cross-reactivity with seasonal coronaviruses,
22 of the PreCOVID panel were analysed using pVNT. All samples gave titres of <1:40,
which were classed as negative for SARS-CoV-2 antibodies (data not shown). To further
confirm the use of pVNT as an alternative to VNT, the pVNT was performed on the
time-course of sera from the three individuals in the Sym group, which was previously
tested (Figure 3), using the pseudotype virus generated at APHA. Analysis showed that for
person 1, antibody levels remained high and relatively constant throughout the time-course
(Figure 5B), whilst patients 2 and 3 showed a small decrease in antibody titre until 62 and
48 days post symptoms respectively, after which antibody levels plateaued. The analysis of
all three different cohorts (Sym, UHS+ve, Sym time course) have demonstrated that the
pseudotype virus can be used to analyse antibody responses against SARS-CoV-2.
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Figure 5. Reproducibility of pseudotype SARS-CoV-2 virus neutralisation test (pVNT) and comparison to the SARS-
CoV-2 virus neutralisation test (VNT). (A) Titres from the pVNT, conducted and analysed independently at two separate
institutions, from a subset of sera from individuals that had symptomatic disease consistent with SARS-CoV-2 infection
during the pandemic tested by VNT and ELISA in Figure 1. (B) pVNT titres from samples taken for up to 93 or 97 days post
symptom onset from three COVID-19 symptomatic individuals tested in Figure 2. (C–E) Comparison between SARS-CoV-2
VNT and pVNT on a subset serum samples from a group of PCR positive human patient sera from the University Hospitals
Southampton NHS Foundation Trust. Comparison of pVNT titres on the serum panel using independently generated
pseudotyped viruses from three separate locations; (C) APHA (institution 1), (D) University of Kent (Institution 2) and (E)
University of Sussex (institution 3).
To further analyse the use of pVNT as an alternative to traditional VNT, a panel of
serum from the UHS+ve COVID-19 confirmed patients was selected based on the titres
from VNT, NP-ELISA, and Whole Antigen ELISA. The panel consisted of 23 serum samples,
including those with (i) high VNT titres (>70 VNT IC50 [n = 4]), (ii) medium VNT titres (>8
and <20 [n = 4]), (iii) low VNT titres (>2.8 and <8 [n = 4]), (iv) ELISA negative and VNT
positive (n = 3), (v) ELISA positive and VNT negative (n = 4), and (vi) ELISA negative and
VNT negative (n = 4). To investigate the reproducibility of pVNT for diagnostic activities,
the pVNT was analysed using a SARS-CoV-2 pseudotype virus generated at three different
institutions (APHA (institution 1), The University of Kent (institution 2) and The University
of Sussex (institution 3)), with all analysis carried out at APHA.
All (100%) of the high, medium, and low VNT titre sera (4/4, high; 4/4, medium; 4/4,
low) were identified as containing neutralising antibody by pVNT using the pseudotype
virus generated at all three institutions (Figure 5C–E). A total of 100% (4/4) of the double
negative (ELISA negative and VNT negative) samples were identified as negative by the
pVNT at all institutions (Figure 5C–E). The pVNT positivity of the three ELISA negative and
VNT positive was quite variable; 3/3, 2/3, and 1/3 of these sera tested positive by pVNT
at institutions 1, 2, and 3 respectively. Similarly, the ELISA positive and VNT negative sera
exhibited a high variability in positivity by pVNT; 0/4, 3/4, and 0/4 of these sera tested
positive via the pVNT. There was also a strong correlation between VNT and pVNT titres
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for the VNT positive sera, with R2 values of 0.8092, 0.7084, and 0.7405 for institutions 1, 2,
and 3, respectively (data not shown).
4. Discussion
Antibody detection and quantification methods are critical to assessing asymptomatic
infection, post clinical convalescence, and post-vaccine responses to COVID-19. Population-
based studies have given an intriguing insight into potential levels of herd immunity
across asymptomatic and symptomatic individuals. However, what the outputs mean
regarding population level protection is hard to define. Several population-level studies
have attempted to use serological outputs to indicate the level of virus spread, both in
the presence and absence of clinical disease, as well as serological titres following severe
infection and convalescence. A report detailing serological responses in 61,000 individuals
from Spain demonstrated that 5% of sampled individuals had antibodies specific for the
spike and nucleoproteins of SARS-CoV-2 [35]. Interestingly, from this cohort, approximately
33% of sampled individuals were asymptomatic. This, as we now understand, reflects the
high level of asymptomatic infection, which in turn links to the rate of transmission as well
as the low case fatality rate. Neutralising antibody longevity has also been questioned,
with some reports suggesting that sero-positivity wanes during convalescence, although
larger studies are required. As mentioned above, some reports have suggested a correlation
between clinical disease status and serological positivity; low disease severity correlating
with a transient antibody response [25] and also with neutralising IgA antibodies [36].
Conversely, an Icelandic study demonstrated a high seroprevalence in those that developed
clinical disease, and antibody levels were generally maintained within the first 4 months
post-infection [37].
Here, we have assessed three cohorts utilising three different assays to evaluate
the relevance of biological testing for antibody responses and, for a small cohort, the
longevity of the antibody response. Previous studies have demonstrated that ELISA out-
puts can correlate quite well with neutralising antibody responses [25,36] and demonstrated
high estimates of seropositivity in infected individuals, from ≈70% to 95% in some stud-
ies [16,19,25,38]. These positivity rates are dependent on time post symptom onset and also
likely depend on clinical disposition and viral dose. However, ELISA has been demonstra-
bly useful in the identification of exposed, asymptomatic contacts of SARS-CoV-2 patients,
such as medical staff [39]. A high specificity also appears to be possible using ELISA
platforms, from 95% to 100% [38,39]. One potentially confounding factor for antibody test
specificity is that of cross-reactivity with seasonal alphacoronaviruses (NL63 and 229E) and
betacoronaviruses (OC43 and HKU1). The data presented here demonstrate the utility of
both live virus-based neutralisation assays as well as ELISAs that detect all binding antibod-
ies, regardless of their role in neutralisation. For the negative control cohort, we assessed
138 serum samples taken before the emergence of SARS-CoV-2, and as such, these sera
represent true negative control sera. When assessing the ability of these sera to neutralise
SARS-CoV-2, none were able to neutralise the virus, suggesting that the cross reactivity
of antibodies to seasonal coronaviruses are unlikely to play a role in the neutralisation of
SARS-CoV-2, although there is evidence of cross neutralisation to some [40]. However, to
assess this more thoroughly, either VNTs specific for seasonal coronaviruses need to be
developed or specific sera raised against seasonal non-SARS-CoV-2 strains. Additionally,
antibody detection by ELISA does not provide any information regarding the protection
offered by antibodies. The extent to which seasonal coronaviruses may cloud serological
outputs has also hampered efforts to define sero-status. Regardless, it is widely accepted
that serological assays are required to define the prevalence of antibody responses across
populations and any resulting humoral immunity associated with responses.
Our data illustrate the potential usefulness of applying VNT and ELISA antibody tests
in parallel to enhance the sensitivity of infection detection. This enhanced sensitivity being
largely due to ELISA tests identifying infected individuals before neutralising antibodies
can be detected and also recognising that VNT can identify infected persons that test
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negative by ELISA. The level of enhanced sensitivity also depends upon the ELISA test
used. We generated a relatively crude Whole Antigen ELISA using BPL-inactivated virus-
infected whole Vero E6 culture extract and compared it with a commercial ELISA test, the
SARS-COV-2-N ELISA kit (IDvet). Both ELISAs had an equally high specificity of 97.8%
and moderate sensitivity that was broadly equivalent to that of VNT testing. The parallel
VNT and ELISA testing of 103 COVID patients showed that proportionally more patients
were detected using the Whole Antigen ELISA in parallel with VNT (75%), compared to
the SARS-COV-2-N ELISA in parallel with VNT (65%), both ELISA tests enhancing the
sensitivity of VNT alone (53%).
Interestingly, SARS-COV-2-N ELISA readouts correlated much better with VNT read-
outs than did the Whole Antigen ELISA. Whether this was due to a lower sensitivity of the
SARS-COV-2-N ELISA that meant that SARS-COV-2-N-positives were more likely to be
VNT-positive is possible; the ROC analysis suggested a lower SARS-COV-2-N sensitivity
compared to the Whole Antigen ELISA, and sequential samples from COVID-19 symp-
tomatic individuals assessed by SARS-COV-2-N ELISA also suggested a loss of sensitivity
over time that was not observed using the Whole Antigen ELISA. The slightly higher
sensitivity of the Whole Antigen ELISA compared to the SARS-COV-2-N ELISA may have
been due to the nature of the crude antigen used, providing a broader target for polyclonal
antibodies in serum samples.
The Whole Antigen ELISA approach allows for flexibility in that new virus strains can
be grown and used as antigen without exactly knowing what the antigenic alterations are.
This is especially important considering the emergence of new SARS-CoV-2 viral variants
that may exhibit different antigenic properties. In addition, this method lends itself to
comparative testing alongside seasonal and other coronavirus crude antigens. However,
for a wider diagnostic use, virus cultures would need to be grown to a much higher titre
than we achieved in this study, to allow for a higher antigen dilution for ELISA—and each
antigen batch to go further. Recombinant antigens avoid this issue, but in our experience,
both S1 and Np proteins tested, despite showing positive responses in our sequential serum
samples, had overall poor sensitivity in detecting antibody-positives among the larger
PCR+ cohort.
ELISA tests are relatively rapid tests compared to VNT, taking hours as opposed to
days to set up and retrieve results, but ELISA results, while useful for diagnosis, may not
define whether the antibody response detected is protective (neutralising), whereas VNT
is recognised as a gold standard test for the positive identification of biologically active
neutralising antibody. Therefore, both ELISA and VNT tests have positive credentials to
bring to diagnostics.
The use of pseudotype viruses to probe the antibody responses of containment level 3
viruses has been used previously on a number of occasions [13–15]. Here, we examined
the diagnostic and research applications of pseudotype viruses expressing the SARS-CoV-2
spike proteins as an alternative to VNT. Analysis of samples demonstrated that pseudotype
viruses generated at multiple different sites were both able to detect samples previously
determined positive by traditional VNT methods, with no false positives being detected; in
addition, a strong correlation in antibody levels was observed when comparing pseudotype
virus with traditional VNT, demonstrating a high level of sensitivity and specificity. The
fact that similar results were also determined from three different SARS-CoV-2 pseudotype
virus preparations demonstrates that this is a reproducible assay. Considering that resource-
heavy, high containment facilities are usually needed for handling SARS-CoV-2 virus,
the use of pseudotype viruses may act as a suitable alternative for modelling antibody
responses in regions where these laboratory facilities are not readily available.
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